ENANTA PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Enanta Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2011 to Q2 2024.
  • Enanta Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$22.7M, a 42% increase year-over-year.
  • Enanta Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$115M, a 12.7% increase year-over-year.
  • Enanta Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$134M, a 9.91% decline from 2022.
  • Enanta Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$122M, a 54.1% decline from 2021.
  • Enanta Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$79M, a 118% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$115M -$22.7M +$16.4M +42% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$132M -$31.2M +$6.5M +17.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-07
Q4 2023 -$138M -$33.4M -$4.42M -15.3% Oct 1, 2023 Dec 31, 2023 10-Q 2024-08-07
Q3 2023 -$134M -$28.1M -$1.76M -6.68% Jul 1, 2023 Sep 30, 2023 10-Q 2024-08-07
Q2 2023 -$132M -$39.1M -$7.37M -23.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$125M -$37.7M -$4.07M -12.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-07
Q4 2022 -$121M -$29M +$1.13M +3.75% Oct 1, 2022 Dec 31, 2022 10-Q 2024-08-07
Q3 2022 -$122M -$26.3M -$1.75M -7.11% Jul 1, 2022 Sep 30, 2022 10-Q 2023-02-08
Q2 2022 -$120M -$31.7M -$7.68M -32% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$112M -$33.6M -$11.5M -52.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-08-08
Q4 2021 -$101M -$30.1M -$21.8M -262% Oct 1, 2021 Dec 31, 2021 10-Q 2023-08-08
Q3 2021 -$79M -$24.6M +$4.74M +16.2% Jul 1, 2021 Sep 30, 2021 10-K 2023-11-22
Q2 2021 -$83.7M -$24M -$9.76M -68.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$74M -$22M -$16M -267% Jan 1, 2021 Mar 31, 2021 10-Q 2022-08-08
Q4 2020 -$57.9M -$8.33M -$21.8M -162% Oct 1, 2020 Dec 31, 2020 10-Q 2022-08-08
Q3 2020 -$36.2M -$29.3M -$38.5M -419% Jul 1, 2020 Sep 30, 2020 10-K 2020-11-25
Q2 2020 $2.36M -$14.3M -$21.3M -303% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $23.7M -$6.01M -$10.2M -245% Jan 1, 2020 Mar 31, 2020 10-Q 2021-08-09
Q4 2019 $33.8M $13.4M -$12.6M -48.3% Oct 1, 2019 Dec 31, 2019 10-Q 2021-08-09
Q3 2019 $46.4M $9.19M -$18.2M -66.5% Jul 1, 2019 Sep 30, 2019 10-K 2020-11-25
Q2 2019 $64.6M $7.04M -$13.3M -65.3% Apr 1, 2019 Jun 30, 2019 10-K 2020-11-25
Q1 2019 $77.9M $4.15M -$8.41M -67% Jan 1, 2019 Mar 31, 2019 10-K 2020-11-25
Q4 2018 $86.3M $26M +$14.3M +122% Oct 1, 2018 Dec 31, 2018 10-K 2020-11-25
Q3 2018 $72M $27.4M -$9.09M -24.9% Jul 1, 2018 Sep 30, 2018 10-K 2019-11-27
Q2 2018 $81M $20.3M +$28.7M Apr 1, 2018 Jun 30, 2018 10-K 2019-11-27
Q1 2018 $52.3M $12.6M +$17.9M Jan 1, 2018 Mar 31, 2018 10-K 2019-11-27
Q4 2017 $34.4M $11.7M +$16.7M Oct 1, 2017 Dec 31, 2017 10-K 2019-11-27
Q3 2017 $17.7M $36.5M +$38.3M Jul 1, 2017 Sep 30, 2017 10-K 2018-11-29
Q2 2017 -$20.6M -$8.43M -$7.35M -683% Apr 1, 2017 Jun 30, 2017 10-K 2018-11-29
Q1 2017 -$13.3M -$5.39M -$3.75M -228% Jan 1, 2017 Mar 31, 2017 10-K 2018-11-29
Q4 2016 -$9.5M -$4.98M -$31.2M -119% Oct 1, 2016 Dec 31, 2016 10-K 2018-11-29
Q3 2016 $21.7M -$1.8M -$7.61M -131% Jul 1, 2016 Sep 30, 2016 10-K 2017-12-11
Q2 2016 $29.3M -$1.08M -$3.49M -145% Apr 1, 2016 Jun 30, 2016 10-K 2017-12-11
Q1 2016 $32.8M -$1.65M -$30.4M -106% Jan 1, 2016 Mar 31, 2016 10-K 2017-12-11
Q4 2015 $63.2M $26.2M -$15.8M -37.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-12-11
Q3 2015 $79M $5.81M +$10.9M Jul 1, 2015 Sep 30, 2015 10-K 2016-12-09
Q2 2015 $68.1M $2.42M -$47.6M -95.2% Apr 1, 2015 Jun 30, 2015 10-K 2016-12-09
Q1 2015 $116M $28.8M +$34M Jan 1, 2015 Mar 31, 2015 10-K 2016-12-09
Q4 2014 $81.8M $42M +$47.4M Oct 1, 2014 Dec 31, 2014 10-K 2016-12-09
Q3 2014 $34.4M -$5.04M -$599K -13.5% Jul 1, 2014 Sep 30, 2014 10-K 2015-12-11
Q2 2014 $35M $50.1M +$54.2M Apr 1, 2014 Jun 30, 2014 10-K 2015-12-11
Q1 2014 -$19.2M -$5.2M -$1.45M -38.8% Jan 1, 2014 Mar 31, 2014 10-K 2015-12-11
Q4 2013 -$17.7M -$5.37M -$27.3M -124% Oct 1, 2013 Dec 31, 2013 10-K 2015-12-11
Q3 2013 $9.63M -$4.44M -$391K -9.65% Jul 1, 2013 Sep 30, 2013 10-K 2014-12-11
Q2 2013 $10M -$4.14M -$637K -18.2% Apr 1, 2013 Jun 30, 2013 10-K 2014-12-11
Q1 2013 $10.7M -$3.75M -$35.9M -112% Jan 1, 2013 Mar 31, 2013 10-K 2014-12-11
Q4 2012 $46.5M $22M +$25.1M Oct 1, 2012 Dec 31, 2012 10-K 2014-12-11
Q3 2012 $21.4M -$4.05M Jul 1, 2012 Sep 30, 2012 10-K 2013-12-18
Q2 2012 -$3.5M Apr 1, 2012 Jun 30, 2012 10-K 2013-12-18
Q1 2012 $32.1M Jan 1, 2012 Mar 31, 2012 10-K 2013-12-18
Q4 2011 -$3.16M Oct 1, 2011 Dec 31, 2011 10-K 2013-12-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.